Clinical Trials
12 trialsNCT05155332 2026-05-20
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Suspended
NCT06265727 2026-01-08
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Corbus Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT04058756 2025-10-07
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
Novartis
Phase 1 Active not recruiting
NCT03034304 2025-07-24
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
HRYZ Biotech Co.
Phase 1 Terminated
NCT06603844 2025-06-03
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
Corbus Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT04237649 2025-05-18
KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors
Novartis
Phase EARLY_PHASE1 Terminated
NCT04672434 2024-12-09
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Symphogen A/S
Phase 1 Completed
NCT03523819 2024-09-19
A Study of CS1002 in Subjects with Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1 Completed
NCT05204862 2023-04-03
Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors
TiumBio Co., Ltd.
Phase 1/2 Recruiting
NCT02460224 2022-02-10
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis
Phase 1/2 Completed
NCT03704246 2021-03-04
Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors
Taizhou Hanzhong biomedical co. LTD
Phase 2 Unknown
NCT04478461 2020-11-13
Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1 Unknown